LEPU BIO

2157
2.6601.48% ( -0.040 )
Delay Closed: Nov 16, 16:08:11

Overview

LEPU BIO (2157)

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted th...

Open
2.715
High
2.715
Low
2.600
Prev. Close
2.700
Volume
10.43M
Turnover
27.68M
Avg Price
2.654
Bid/Ask Ratio
-61.54%
Amplitude
4.26%
52wk High
6.650
Volume Ratio
1.04
Turnover Ratio
0.58%
52wk Low
2.600
HK Mkt Cap
4.80B
Market CapHKD
4.80B
P/ETTM
16.88
P/EDynamic
76.09
P/EStatic
--
EPSTTM
0.158
EPSDynamic
0.0350
EPSStatic
--
BVPS
0.90
P/B
2.95
HK Shares
1.80B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.80B
Min lot size
1,000
Currency
HKD

LEPU BIO Analyst Rating

View more

Forecast & Rating

Apr 18, 2026
Price forecast
HK$10.38290.23%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Lepu Biopharma closed up 5.80% at HK$4.380, with notable turnover of HK$49.8 million, driven primarily by the milestone of exiting the biotech marker regime after meeting HKEX Mainboard tests. The stock edged higher in the morning session, dipped to an intraday low before rebounding sharply in the afternoon to a session high of HK$4.400, finishing near its best level. The company reported a full-year net profit of approximately HK$122 million, representing a stunning 205% YoY surge, while operating revenue expanded 109% to HK$261 million, marking its first profitable year. Despite this positive fundamental shift, the stock remains 58% below its 52-week high of HK$10.5 and trades below the 60-day moving average of HK$4.729, though it has now moved well above the 20-day MA of HK$3.818, indicating improving near-term momentum amid a still-uncertain medium-term trend.

News

Bullish vs. Bearish — Last 3 Months

2.2k followers · 0 opinions
▲Bullish50%
50%Bearish▼